CD274 and small cell lung carcinoma: In phase 3, randomized, open-label CASPIAN study, another PD-L1 inhibitor durvalumab plus platinum-etoposide as first-line treatment for ES-SCLC patients resulted in consistent and durable clinical benefit across overall survival (OS), progression-free survival (PFS), and objective response compared with a clinically relevant control group [13].